Pathology and Lab Medicine

Host: Brian P. McDonough, MD, FAAFP

Guest: Marie Wood, MD

Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.

Host: Ryan Quigley

Guest: Hallie Blevins, PhD.

Guest: Marlene Mimi Maeusli, PhD.

With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection.

Reference:

Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

Host: Ashley Baker, MSN, PMHNP

Guest: Heather Allen, PhD

Guest: Ran Li, PhD

Fourier Transform Infrared (FTIR) spectroscopy is emerging as a powerful tool for distinguishing cancerous from noncancerous tissue during colorectal cancer surgery. In a recent study, Drs. Heather Allen and Ran Li leveraged a broad dataset from multiple sources to identify and validate biomarkers—most notably B1—that demonstrated strong correlation with standard pathology. Hear Drs. Allen and Li walk through their study and the implications of its findings with Ashley Baker. Dr. Allen is a Full Professor in the Department of Chemistry and Biochemistry as well as the Department of Pathology at Ohio State University in Columbus, and Dr. Li is a researcher who completed a PhD in Analytical Chemistry at The Ohio State University in 2015.

Guest: Fernando López-Ríos, MD, PhD

Guest: Christian Rolfo, MD, PhD

Guest: Charlie Gourley, MD, PhD

In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.

Topics of conversation include the following:

• An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
• Targeting HER2 in lung cancer: where does IHC testing fit in?
• Ovarian cancer: challenges and considerations for HER2 IHC testing

Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.

The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease.

FA-11319389 12/24

Guest: Donald Kohan, MD, PhD

Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City.

References:

1. Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143
2. Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023
3. Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321
4. Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301
5. Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670

FA-11319389 12/24